The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...